Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NED-170
- Development stage
- Unknown
- Lead developer
- NED Biosystems
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NED-170** is an investigational oral fixed-dose, seven-component anticancer combination developed by NED Biosystems for advanced solid tumors. It combines alpha-lipoic acid, curcumin, cyclophosphamide, genistein, melatonin, metformin, and naltrexone in a low-dose systems-treatment regimen intended to concurrently modulate cancer-driving processes including angiogenesis, impaired apoptosis, altered tumor metabolism, and immune evasion. The program has been described for cholangiocarcinoma, ovarian cancer, and triple-negative breast cancer, including use alongside standard care in patients without an actionable tumor-genomic target. ([nedbiosystems.com](https://nedbiosystems.com/press/ned-biosystems-gains-patent-for-unique-combination-therapy/))
02
Targets
N7-G (DNA guanine-N7 adduct)DNATOP2A (DNA topoisomerase II)ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)PTK (Protein-Tyrosine Kinase)
Beyond the preview
Go deeper on NED-170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NED-170.